Truls Sylvan Ingebrigtsen
Overview
Explore the profile of Truls Sylvan Ingebrigtsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
647
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marott J, Ingebrigtsen T, Colak Y, Vestbo J, Nordestgaard B, Lange P
Respir Med
. 2024 Feb;
224:107557.
PMID: 38355020
Background: Risk of exacerbations in individuals with mild chronic obstructive pulmonary disease (COPD) in the general population is less well described than in more advanced disease. We hypothesized that in...
2.
Marott J, Ingebrigtsen T, Colak Y, Kankaanranta H, Bakke P, Vestbo J, et al.
Lancet Reg Health Eur
. 2023 Nov;
35:100759.
PMID: 38023334
Background: Whether the metabolic syndrome plays a role for the prognosis of individuals with lung function impairment (preserved ratio impaired spirometry (PRISm) or airflow limitation) is unclear. We hypothesised that...
3.
Soendergaard M, Hansen S, Bjerrum A, von Bulow A, Haakansson K, Hilberg O, et al.
J Allergy Clin Immunol Pract
. 2023 Oct;
12(1):146-155.e5.
PMID: 37832820
Background: Randomized trials of biologics in severe, uncontrolled asthma have excluded patients with a cumulative tobacco exposure of more than 10 pack-years. Therefore, our knowledge of the impact of smoking...
4.
Heerfordt C, Ronn C, Harboe Z, Ingebrigtsen T, Svorre Jordan A, Wilcke J, et al.
BMJ Open Respir Res
. 2023 Sep;
10(1).
PMID: 37775111
Background: Inhaled corticosteroids (ICSs) are associated with an increased risk of pneumonia among patients with chronic obstructive pulmonary disease (COPD). The introduction of extrafine particle ICS has aimed to improve...
5.
Heerfordt C, Eklof J, Sivapalan P, Ingebrigtsen T, Biering-Sorensen T, Harboe Z, et al.
Int J Chron Obstruct Pulmon Dis
. 2023 Mar;
18:373-384.
PMID: 36974273
Background: Inhaled corticosteroids (ICS) are associated with an increased risk of clinical pneumonia among patients with chronic obstructive pulmonary disease (COPD). It is unknown whether the risk of microbiologically verified...
6.
Meteran H, Tonnesen L, Sivapalan P, Ingebrigtsen T, Jensen J
Breathe (Sheff)
. 2022 Nov;
18(1):210178.
PMID: 36338257
https://bit.ly/3KE1BH4.
7.
Soendergaard M, Hansen S, Bjerrum A, Hilberg O, Lock-Johansson S, Hakansson K, et al.
ERJ Open Res
. 2022 Oct;
8(4).
PMID: 36199589
Background: Phase III regulatory trials show that anti-interleukin (IL)-5 biologics efficiently reduce exacerbations and the use of maintenance oral corticosteroids (mOCS) in patients with severe eosinophilic asthma. However, patients eligible...
8.
Mohsin R, Heerfordt C, Eklof J, Sivapalan P, Saeed M, Ingebrigtsen T, et al.
J Clin Med
. 2022 Jun;
11(12).
PMID: 35743610
Background: Inhaled corticosteroids (ICS) are widely used in chronic obstructive pulmonary disease (COPD), despite the known risk of severe adverse effects including pulmonary infections. Research Question: Our study investigates the...
9.
Marott J, Colak Y, Ingebrigtsen T, Vestbo J, Nordestgaard B, Lange P
Respir Med
. 2021 Dec;
192:106725.
PMID: 34972025
Background: Whether risk of exacerbations of chronic obstructive pulmonary disease (COPD) is influenced by severity of symptoms and maintenance treatment is unclear. Objective: We hypothesized that in addition to history...
10.
Eklof J, Ingebrigtsen T, Sorensen R, Saeed M, Alispahic I, Sivapalan P, et al.
Thorax
. 2021 Aug;
77(6):573-580.
PMID: 34446524
Background: Inhaled corticosteroids (ICS) are commonly used to treat COPD and are associated with increased risk of pneumonia. The aim of this study was to assess if accumulated use of...